This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Our mission is to accelerate the commercialization of breakthrough innovations like the AUTAC platform for health impact, and we welcome Automera and ALSP to Singapore’s growing lifesciences translational community.” We invest and partner with innovators, entrepreneurs, and founders to launch and grow global companies in Singapore.
By simulating trials at scale, QuantHealth’s platform can lower risks, expedite, and optimize drugdevelopment. QuantHealth is already working with several global pharmaceutical companies to use its product in clinical trial design and development. Petra Jantzer, Ph.D., Originally announced January 8th, 2024
With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the lifesciences and healthcare sector. However, they are vital to the drugdevelopment and approval process and critical in enabling access to innovative medicines.
In our interview, Gil emphasizes the critical role of AI in expediting the discovery of new drugs, citing the lengthy and costly nature of traditional drugdevelopment processes. However, with AI-driven approaches, Aion Labs is paving the way for a paradigm shift in drug discovery.
That is the opinion of Ron Emerson, RN, global healthcare lead at Zoom, as he looks ahead at what he believes will be some developments in healthcare in 2022. You predict that decentralization will become a major theme for health and lifescience organizations. Please elaborate.
The development and manufacturing process for these important new drugs is very different from traditional medicines. This article focuses on the technology that ensures quality in the process, and is based on a conversation with Graziella Piras, PhD, LifeScience Business Development Director at 908 Devices.
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drugdevelopment, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
This strategic consolidation establishes PicnicHealth as the leading patient-centric evidence-generation partner within a rapidly evolving lifesciences landscape. By combining forces, we can unlock the potential of patient-centered studies and provide best-in-class solutions to support therapeutic development.”
Deerfield invests across the lifescience, medical device, diagnostic, digital health, and health service industries at every stage of evolution. The company will use this new funding to further expand its real-world data platform and services in order to drive more efficient and inclusive drugdevelopment in oncology.
This transformation will particularly benefit organizations that can effectively combine AI expertise with traditional pharmaceutical knowledge, creating new competitive advantages in drugdevelopment efficiency, cost management, and market responsiveness.
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drugdevelopment. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drugdevelopment.
This platform is designed to meet the demands of health systems and lifescience companies working to solve increasingly global, diverse, and data-intensive healthcare problems. Atropos’ unique global offerings help lifescience leaders overcome this challenge.
Furthermore, by fostering connectivity and automating tasks, DHTs reduce administrative burdens, accelerate recruitment, and improve overall trial transparency, ultimately contributing to faster and more reliable drugdevelopment.
The seed round was co-led by Wellington Partners and Forbion and includes non-dilutive financing from BMBF GO-Bio, a prestigious German government initiative aimed at supporting the most innovative startups in the lifesciences. Forbion invests in lifesciences companies that are active in the (bio) pharmaceutical space.
Traditionally, the prudent lifesciences industry purchases novel technology incrementally at the study level. Without the economies of scale, this approach often comes with higher service costs. Learn more about what is driving sharp eCOA growth at the annual SCOPE meeting (Feb 3-6, 2025) in Orlando, booth #717.
We are particularly excited about the ability of these tools to drive more efficient and faster drugdevelopment processes in the biopharma industry.” “The About Novalis LifeSciences LLC Novalis LifeSciences is the investment arm of Novalis Capital Partners, a boutique investment and advisory firm for the LifeScience industry.
Founded in 2018 and supported from the outset by LallianSe, the lifesciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drugdevelopers and physicians – neurologists, neuroradiologists and intensivists.
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and lifesciences firms, and insurance companies serve patients as end users. The same definition of patient engagement applies to industry, except that the interventions lead to more human centered design and value-based care.
Jane Reed, Director of LifeSciences at Linguamatics, an IQVIA company Pharmaceutical developers have always prioritized drug safety. Discussions will focus on the nuanced packaging and delivery requirements for MABs, emphasizing the commitment to safety standards while ensuring the drugs’ effectiveness.
QuantHealth bridges these gaps by simulating trials at scale, to expedite, derisk, and optimize drugdevelopment. This decline is happening at a time when the need for efficient drugdevelopment has never been greater. This happens because there are major gaps in the research needed to support clinical trials.
.” Prognos Health’s platform is used by over 70 lifesciences customers to accelerate the development of new drugs, improve the safety and efficacy of existing drugs, and identify new patient populations that may benefit from specific treatments.
Blockchain technology’s potential impact on the lifesciences industry (drugdevelopment, distribution and prescribing) is significant. It can impact the opioid crisis and improve tracking drugs in the supply chain.
AI-powered* platform takes eCOA off the critical path to study startup for lifesciences industry PALO ALTO, Calif.–(BUSINESS –(BUSINESS WIRE)– Medable Inc. , Medable, which ranked in the top 8% of software companies on the 2023 Inc.
Their expertise in company building, capital formation, and drugdevelopment will be a tremendous resource to Avilar as the innovation leader in the new field of extracellular protein degradation.” For more information, please visit www.avilar-tx.com and follow us on Twitter @Avilar_Tx and on LinkedIn.
Chris McSpiritt, Head of LifeSciences at Domino Data Lab Next year will see AI-enhanced imaging technologies significantly improve diagnostic accuracy in radiology and pathology, empowering clinicians to make quicker and more reliable decisions at the point of care. Today, it’s largely restricted to genomics and oncology.
As precision medicine becomes more nuanced and complex, biopharmaceutical companies are increasingly turning to AI to enhance the utility, performance, and scalability of computational pathology analyses for drugdevelopment and diagnostics. Aignostics is funded by leading investors and has operations in Berlin and New York.
Aviceda Glycotech looks forward to this collaboration aimed at developing the next generation of cancer checkpoint immune therapeutics in Belfast. “It Its mission is to improve patient outcomes, train the next generation of scientists and clinicians, and enhance the competitiveness of the UK lifesciences sector.
Investments will focus on the next generation of pharma R&D to accelerate drugdevelopment, on new technology solutions enabling a more patient-centric approach in clinical trials, and on digital platforms uncovering new insights from clinical data for more personalized care pathways.
Mountain Group Partners is an investor dedicated to investing in and actively guiding transformational businesses in the Technology, Animal Health, and LifeSciences sectors. Technology investments focus on business and healthcare technology, targeting those ideas with quantifiable development risk and a rapid path to market.
The new company aims to leverage its extensive data sets and technology to provide innovative solutions across various healthcare sectors, including lifesciences, provider, imaging, health plan, employer, and government health and human services.
Cornerstone’s founders incubated the company in partnership with Initiate Studios, a new venture studio that co-creates companies at the intersection of healthcare, lifesciences and technology. Poor quality data leads to drugdevelopment being delayed, patients being misdiagnosed and inaccurate scientific conclusions.
These individuals have personally built leading technology platforms supercharging drugdevelopment globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Dr. Bernd Seizinger, M.D.,
Life-sciences companies recorded the strongest gains, Fenwick found, with their valuations rising 110% compared with their prior funding rounds. But key facets of its business didn’t develop as planned, say people familiar with the company.
Pharmaceutical and LifeSciences Companies: These companies are looking for HealthTech solutions to: Enhance clinical trials and drugdevelopment processes. Develop personalized medicine approaches. Examples: CVS Health acquiring telemedicine provider Aetna, Ascension acquiring teleICU company Aidiant.
The WHO and the India G20 presidency emphasised its importance by launching ‘The Global Initiative of Digital Health’ (GIDH) in August, proclaiming: “Digital health is a proven accelerator to advance health outcomes and achieve Universal Health Coverage and health-related Sustainable Development Goals.”
Food and Drug Administration, biomedical and lifescience companies, nonprofits, patient-focused groups, and other organizations to transform the current model for developing new diagnostics and treatments. ALS is a progressive and ultimately fatal neurological disease with few treatment options and no cure yet.
The majority of healthcare and lifesciences executives (82%) want to see their organizations more aggressively adopt AI technology, according to a new survey from KPMG, an audit, tax and advisory services firm. However, lifesciences companies seem to be struggling to select the best AI technologies, according to 73% of executives.
Jesse Cugliotta, Global Industry GTM Lead, Healthcare & LifeSciences at Snowflake. Patient insight management will be a key strategic pillar: Lifescience organizations are more confident in the business value of insights management and are increasingly willing to commit the necessary technological resources to support this need.
Precision medicine will continue to evolve in 2024: In disease areas like oncology, we will start to see AI playing a larger role in target discovery and biomarker or patient subpopulation identification, the cornerstones to early precision drugdevelopment.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content